Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ulcerative Colitis: Update Bulletin [December 2017]

Product Code:
596200941
Publication Date:
December 2017
Format:
PDF
Price:
£910

This edition presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include: Takeda and Portal Instruments announcing the production of a needle-free formulation of Entyvio (vedolizumab); Qu Biologics reporting that QBECO achieved high clinical and endoscopic response ratesin a Phase II trial conducted in patients with moderate-to-severe UC; Protagonist Therapeutics announcing the initiation of dosing in a Phase I study of PTG 200, an agent which it is developing in collaboration with Janssen Biotech for inflammatory bowel disease (IBD) and other autoimmune conditions; Weill Cornell Medicine and NewYork-Presbyterian presenting results from a study investigating the use of faecal microbiota transplantation (FMT) in patients with UC.

Business Questions:

• Are the new formulations of Entyvio likely to provide any benefit to patients with UC?
• Is the development of both a needle-free and subcutaneous formulation of Entyvio necessary?
• Does QBECO’s composition, based on enteropathic Escherichia coli components, provide a rational basis for the agent’s development as a UC therapy?
• Where is PTG 200 most likely to be positioned within the UC treatment algorithm in the future?
• Do KOLs think that the scientific rationale underlying FMT’s activity supports its development as a treatment for UC and/or other diseases?
• Do KOLs have any concerns about the safety of the FMT procedure?





customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved